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BY-NC-ND license (http://creativecomAbstract Objective: To evaluate the efficacy and safety of Chinese herbal medicine (CHM)
for the treatment of functional dyspepsia (FD).
Methods: Web of Science, PubMed, EMBASE, Cochrane Library, and four other Chinese
electronic databases, including China National Knowledge Infrastructure (CNKI), Chinese
Biological Medical Database (CBM), Chinese Scientific Journals Database (VIP), and WanFang
Database were used to search (up to Feb, 2016) for randomized, double-blind, placebo-
controlled trials recruiting adults with FD treated with CHM. Study selection, data extrac-
tion, quality assessment, and data analyses were conducted based on Cochrane standards
using Review Manager software.
Results: Fourteen publications (1424 patients) were included. Evidence revealed that CHM
was more efficacious than the placebo in improving global dyspepsia symptoms (RR, 1.45;
95% CI, 1.31e1.60), Chinese medicine syndrome (CMS) (RR, 1.36; 95% CI, 1.23e1.50), and
quality of life (SMD, 0.30; 95% CI, 0.15e0.45) in FD patients. Furthermore, the difference
in the incidence of adverse events between CHM and placebo groups had no statistical
significance (RR, 1.06; 95% CI, 0.66e1.70).W. Wei).
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16.09.006
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148 Y. Guo et al.Conclusion: This meta-analysis demonstrates that CHM has a therapeutic potential in treat-
ing FD with a certain safety. However, due to the restricted number of trials included, well-
planned, long-term studies are necessary to provide credible evidence.
ª 2016 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
As defined by Rome III criteria, functional dyspepsia (FD) is
associated with several upper gastrointestinal symptoms,
including postprandial fullness, early satiety, epigastric pain
or discomfort lasting for 6 months or longer, without an
organic explanation.1 Based on the dominant symptoms, FD
can be separated into two subtypes, postprandial distress
syndrome (PDS) and epigastric pain syndrome (EPS).2 Ac-
cording to Rome III criteria, the estimated prevalence of
uninvestigated dyspepsia (UD) and FD is in the range of
9.8%e20.2% in the West and between 5.3% and 12.8% in the
East,3 with a global prevalence between 4.6% and 11.3%.4 FD
is considered a functional gastrointestinal disorder (FGID)
and follows a chronic and fluctuating course.5 Up to 15%e
20% of patients claim to have persistent symptoms,6 and this
condition negatively impacts physical and mental health as
well as quality of life. Nearly 42% of people with FD consult a
physician though many patients do not seek medical
advice,7 resulting in decreased work productivity due to
poor health.8 A burden of illness study found that in 2009
costs associated with FD in the United States were estimated
at $18.4 billion.9 Given the health and economic burdens of
FD, its effective management is vitally important. However,
because of the nonspecific symptoms and varied pathogen-
eses of this disease, definitive therapy that is beneficial for
all individuals is still lacking.1,10 Conventional treatments,
including lifestyle adjustments, antacids, prokinetic drugs,
psychotropic agents, and even Helicobacter pylori eradi-
cation, often remain unsatisfactory.11e13 Therefore, up to
50% patients seek other therapies, such as complementary
and alternative medicine (CAM).14
One such CAM is traditional Chinese medicine (TCM), of
which an essential branch is Chinese herbal medicine (CHM).
CHM as represented by herbal formulation is an organic
combination of Chinese herbs in based on the theories of
TCM. CHM appears to have a regulatory effect on the human
body and clinical and experimental studies seem to indicate
that herbal therapy is an encouraging option for the treat-
ment of FD.15 Several meta-analyses have been conducted
to evaluate the therapeutic benefits of CHM compared with
Western medicine, mainly prokinetic drugs. However, evi-
dence from these studies has been weak. Furthermore,
these studies have been limited by use of specific herbal
formulations, such as Pinellia Decoction to Drain the Epi-
gastrium (Banxia Xiexin Tang) or Modified Rambling Powder
(Xiao Yao San Jia Jian).16e19 Therefore, the therapeutic
value of CHM for FD is unknown. To address this question, we
conducted a meta-analysis of clinical trials on the CHM
treatment of FD, we aimed to determine the efficacy and
the safety of CHM and to make recommendations on future
investigations of the clinical usage of CHM in treating FD.Methods
Data sources and search strategy
Articles published up to February 11, 2016 were retrieved
from 8 electronic databases: Web of Science, PubMed,
EMBASE (Excerpt Medica Database), Cochrane Library, and 4
Chinese electronic databases, including China National
Knowledge Infrastructure (CNKI), WanFang Database, Chi-
nese Biological Medical Database (CBM), and Chinese Scien-
tific Journals Database (VIP). CNKI and WanFang databases
were used to search for conference proceedings and disser-
tations from unpublished clinical trials. Studies were iden-
tified using the following search terms were as in this
PubMed example: “randomized”[Title/Abstract] AND
“placebo”[Title/Abstract] AND (“blind”[Title/Abstract] OR
“blinded”[Title/Abstract]) AND (“Traditional Chinese Medi-
cine”[Title/Abstract] OR “Chinese Medicine, Traditional”
[Title/Abstract] OR “Medicine, Chinese Traditional”[Title/
Abstract] OR “Chinese Traditional Medicine”[Title/Abstract]
OR “Herbal Medicine”[MeSH Terms] OR “Herbal Medicine”
[Title/Abstract] OR “Medicine, Herbal”[Title/Abstract] OR
“TCM” [Title/Abstract] OR “herb”[Title/Abstract] OR
“Medicine, Chinese Traditional”[Mesh] OR “formula”[Title/
Abstract] OR “decoction”[Title/Abstract] OR “kampo”
[Title/Abstract]) AND “functional dyspepsia”[Title/
Abstract]. The Chinese equivalent translations were also
searched in Chinese databases.Inclusion/exclusion criteria
Randomized, double-blind, and placebo-controlled clinical
trials that compared CHM with a placebo were included.
The full-text articles had to be published in English or
Chinese.
Participants (not limited to specific groups of the pop-
ulation) who were diagnosed with FD based on Rome
criteria, including Rome I, II, and III, were included. All
participants were aged 18 years or older.
The treatment groups only received CHM by oral
administration in any form of preparation, including de-
coctions, extracted granules, capsules, tablets, powders,
and liquids. Placebos, which were identical in appearance,
taste, and smell, were compared to the herbal medicines
and used alone in the controlled group. The minimum
duration of therapy and follow-up was 7 days.
In terms of outcome measures, studies were included if
dichotomous assessment of responses to therapy based on
the effect of CHM or the placebo on global dyspepsia symp-
toms was used as a measurement for the primary outcome,
with a preference for patient-reported assessment if the
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reported results, and secondary outcomes were measured
using Chinese medicine syndrome (CMS) improvement,
quality of life, and adverse events. However, clinical trials
without dichotomous outcomes in global dyspepsia symp-
toms, butwith information on CMS improvement or quality of
life, were also included. Studies, based on one clinical trial
but published as separate articles with varied outcome
measures, were merged as a single study.
Data extraction
All data were extracted separately by two investigators (Y
G and JJ Z), where disagreements were determined by
consensus with the corresponding author (W W). Extracted
information included country of origin of the study, diag-
nostic criteria and subtypes, TCM syndrome differentiation,
population and baseline characteristics, interventions,
duration of therapy, follow-ups, outcome measurements,
and adverse events.
Assessment of quality
Two investigators (Y G and JJ Z) used the Cochrane risk of
bias tool,20 to evaluate methodological quality, and dis-
agreements were resolved by discussion and consensus with
the corresponding author. Quality of included trials was
evaluated for generation of randomization, concealment of
allocation, blinding method, incomplete outcome data,
selective reporting, and other bias.
Data analysis
Data processing and analysis were performed using Review
Manager version 5.2.7 (Cochrane Collaboration, Oxford,
UK). Dichotomous data were represented as relative risk
(RR) and continuous variables were compared using mean
difference (MD), both with 95% confidence interval (CI). In
cases where different measurement scales were used,
standardized mean difference (SMD) was chosen instead of
MD. The number needed to treat (NNT), with 95% CI, was
computed based on the formula NNT Z 1/(control event
rate  (1  RR)).21
Heterogeneity, which represents the variation between
individual study results, was evaluated by the c2 test and
the I2 statistic.22 When the P > .10 of c2 test with I2  50%,
the heterogeneity was considered acceptable,23 and the
fixed effects model was adopted. Otherwise, the data were
pooled by using the random effects model.24 Z (u) test was
used for the hypothesis test in order to evaluate the overall
impact of CHM. Differences between CHM and placebo
groups were considered statistically significant when
P  .05, as represented in forest plots.
Results
Description of included studies
A total of 140 citations were identified from the 8 electronic
databases. Of these 140 citations, 34 published articlesappeared to be relevant and were evaluated in full-text, of
which 20 articles were excluded for various reasons (Fig. 1).
Fourteen studies are deemed eligible for inclusion in the
meta-analysis, including 11 journal articles and 3 the-
ses.25e38 Among these 14 articles, 825e28,34,36e38 were
merged into 4 studies,34,36e38 as varied results were reported
in these different articles but all results were derived from a
single clinical trial. Finally, 10 studies were included,29e38 7
of which were completed in China31,32,34e38 with 3 published
in English,36e38 2 were completed in Korea,29,30 and 1 was
completed in Japan (Table 1).33
There were a total of 1424 patients in the 10 studies, and
the total participants in each study ranged from 46 to 273.
The proportion of male patients recruited by the trials
ranged from 30.4% to 47.0%; the proportion of male pa-
tients in one study was unknown.34 Seven studies were
multicenter trials with the total number of centers involved
ranging between 2 and 31.30,33e38 Outcomes of global
symptom improvement were not provided as dichotomous
data in 3 of the trials.29,30,32 Seven trials completed in
China elaborated TCM syndrome differentiation, with 6
reporting CMS improvements in their results,31,32,34e37
while studies completed in Japan and Korea did not
include this information. Moreover, 7 studies adopted
quality of life as one of the outcome measures29e32,34,37,38
and 4 trials included adverse events.29,30,33,35 Specific de-
tails of each study are presented in Table 1, as well as the
composition of CHM used in each eligible study is provided
in Table S1 of the Supplementary Information.
Methodological quality
Most of the included studies elaborated on the specific
methods used in random sequence generation and alloca-
tion concealment. Among the 10 studies, 9 articles stated
blinding methods of participants and inves-
tigators,29,30,32e38 while in 7 articles there was indication of
outcome assessments being conducted by a third
party.29,30,33,34,36e38 Furthermore, 9 of the 10 studies re-
ported dropouts29,30,32e38 and most studies adopted
intention-to-treat (ITT) analyses.29e31,33,34,36e38 However,
only 3 studies were registered as clinical trials online29,33 or
had published a protocol,30,39 while such information for
the 7 other studies were unavailable. Baseline character-
istics in all studies were comparable between the treat-
ment and control groups, but the exact figures were not
provided in 2 of the studies.34,35 Moreover, 5 investigations
had clear statements about competing interests.30,33,36e38
Methodological assessment of included studies was repre-
sented as a graph of From our analyses, we performed risk
bias (Fig. 2A) and a risk bias summary (Fig. 2B).
Global symptom improvement
Dichotomous data on responses to therapy with respect to
its effect on global symptoms were extracted from 7 of the
10 included trials.31,33e38 In total, there were 624 partici-
pants who received CHM therapy and 450 participants who
received placebos. Overall, 468 (75.0%) of 624 patients
assigned to the CHM group reported improved global
dyspepsia symptoms, compared to 217 (48.2%) of 450
Figure 1 Flow diagram of the assessment of studies identified in meta-analysis.
Abbreviations: FD: functional dyspepsia; CHM: Chinese herbal medicine.
150 Y. Guo et al.patients who were part of the placebo group. There was a
therapeutic gain of 26.8% in the CHM group in comparison
with the placebo group, and the NNT value was up to 4 in
the range of 3e7 (Table 2). The results of the heterogeneity
tests (c2 Z 6.50, P Z .37, I2 Z 8%) revealed that the
studies selected were clinically and statistically homoge-
neous. Hence, the fixed effects model was applied in the
meta-analysis. Based on the outcome of the hypothesis test
(Z Z 7.29, P < .00001), the difference in the results be-
tween the CHM and control groups was statisticallysignificant, which indicated that CHM was more efficacious
in improving global symptoms than the placebo (pooled RR,
1.45; 95% CI, 1.31e1.60) (Fig. 3).Chinese medicine syndrome improvement
Six studies (787 participants) reported results of CMS
improvement both in the CHM therapy group and the placebo
group.31,32,34e37 The pooled RR of CMS improvement after
Table 1 Characteristics of included studies of Chinese herbal medicine versus placebos in functional dyspepsia.
First author,
year
Country
(study
centers)
Sample
sizes
(% male)
Diagnostic
criteria
(subtypes)
Syndrome
differentiation
Intervention Durations Follow-up Primary outcomes Secondary outcomes Adverse
events
(T:C)
CHM Placebo
Suzuki et al, 200933 Japan (31) 247(36.8) Rome III
(EPS, PDS,
mixed type)
NR Rikkunshito; powder,
2.5 g, 3 times/day
Powder, 2.5 g,
3 times/day
8 weeks 30 days GPA score 1. Single symptom improvement
(Likert scale)
2. Mean changes in GSRS
3. Weekly changes in GPA
scores and Likert scale
33 (19:14)
Wang et al, 201134;
Zhao et al, 201126
China (5) 104 (NR) Rome III (NR) Spleen-stomach
damp-heat
Gastrosis No.3 compound;
granule, 150 mL,
2 times/day
Granules, 150 mL,
2 times/day
4 weeks 4 weeks 1. TDS (investigator
and patient)
2. SDS (investigator
and patient)
3. CMS improvement
SF-36 0
Che, 201131 China (1) 46 (30.4) Rome III (NR) Exclusion of yin
deficiency syndrome
and blood stasis
Tablets for Clearing and
Resolving and Harmonizing
the Stomach (Qing Hua
He Wei Pian); 4 tablets,
1.2 g, 3 times/day
4 tablets, 1.2 g,
3 times/day
4 weeks 4 weeks 1. Global symptom
improvement (main
symptom score)
2. CMS improvement
1. Single symptom
improvement
2. SF-36
0
Zhang et al, 201337;
Wu et al, 201125
China (5) 162 (34.0) Rome III (NR) Spleen and stomach
deficiency-cold
Gastrosis No.1 compound;
granules, 150 mL,
2 times/day
Granules, 150 mL,
2 times/day
4 weeks 4 weeks 1. TDS scale
2. SDS scale
1. CMS improvement
2. SF-36
0
Zhao et al, 201338;
Zhao et al, 201228
China (5) 101 (33.7) Rome III (NR) Cold-heat complex Modified Pinellia Decoction
to Drain the Epigastrium
(Ban Xia Xie Xin Tang);
granules, 150 mL,
2 times/day
Granules, 150 mL,
2 times/day
4 weeks 4 weeks 1. TDS scale
2. SDS scale
1. SF-36 0
Zhang et al, 201336;
Zhao et al, 201327
China (5) 160 (31.3) Rome III (NR) Spleen deficiency
and qi stagnation
Modified Six Gentlemen
Decoction (Liu Jun
Zi Tang); granules,
150 mL, 2 times/day
Granules, 150 mL,
2 times/day
4 weeks 4 weeks 1. TDS scale
2. SDS scale
1. Gastric emptying using
radiopaque barium markers
2. CMS improvement
0
Xu, 201335 China (3) 273 (34.1) Rome III (NR) 1. Damp-heat stasis
2. Spleen deficiency
and qi stagnation
3. Constrained liver qi
4. Liver-stomach heat stasis
No.1eNo.4 compound;
granules, 2 times/day
Granules,
2 times/day
4 weeks 5 months 1. CMS improvement
2. Global symptom
improvement (main
symptom score)
3. Single symptom
improvement
1. Gastric emptying
using radionuclide
(partially)
3 (2:1)
Park et al, 201330 Korea (2) 100 (47.0) Rome III
(EPS, PDS,
mixed type)
NR Banha-sasim-tang;
granules, 3 g,
3 times/day
Granules, 3 g,
3 times/day
6 weeks 2 months GIS scale 1. VAS
2. FD-QoL questionnaire
3. GMA using
electrogastrography
21 (8:13)
Kim et al, 201429 Korea (1) 170 (23.5) Rome III
(EPS, PDS)
NR Hyangsa-Pyeongwi san;
power, 9.68 g, 3 times/day
Powder, 9.68 g,
3 times/day
4 weeks 4 weeks 1. NDI
2. FD-QoL questionnaire
NR 1 (1:0)
Lu¨, 201432 China (1) 61 (42.6) Rome III
(PDS, mixed
type)
1. Spleen deficiency and
qi stagnation syndrome
2. Spleen deficiency
and damp stagnation
syndrome
3. Spleen yang deficiency
syndrome
No.1eNo.3 compound;
granules, 1 package,
3 times/day
Granules,
1 package,
3 times/day
4 weeks 4 weeks 1. Global symptom
improvement
(based on PDS)
2. CMS improvement
3. Gastric emptying using
ultrasound
1. SF-36
2. HAMA & HAMD
0
Abbreviations: C, control group; CHM, Chinese herbal medicine; CMS, Chinese medicine symptom; EPS, epigastric pain syndrome; FD, functional dyspepsia; FD-QoL, FD-related quality of life;
GIS, gastrointestinal symptom scale; GMA, gastric myoelectric activity; GPA, global patient assessment; GSRS, Japanese version of the Gastrointestinal Symptom Rating Scale; HAMA, Hamilton
Anxiety Scale; HAMD, Hamilton Depression Scale; NDI, Nepean Dyspepsia Index; NR, not reported; PDS, postprandial distress syndrome; SDS, single symptom scale; SF-36, the MOS 36-item
short-form health survey; T, treatment group; TDS, total symptom scale; VAS, visual analogue scale.
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Figure 2 (A) Risk of bias graph of the studies included; (B) risk of bias summary of the studies included.
Table 2 Global symptom improvement in included studies on Chinese herbal medicine versus placebo in functional dyspepsia.
First author, year No. of
participants
Response rate, % (response/N) Therapeutic
gain, %
NNT
(95%, CI)
RR of global symptoms
improving (95% CI)CHM Placebo
Suzuki et al, 200933 247 33.6 (42/125) 23.8 (29/122) 9.8 10 (4, 84) 1.41 (0.95, 2.11)
Wang et al, 201134;
Zhao et al, 201126
104 78.6 (55/70) 55.9 (19/34) 22.7 4 (2, 89) 1.41 (1.02, 1.94)
Che, 201131 46 91.3 (21/23) 30.4 (7/23) 60.9 2 (1, 5) 3.00 (1.60, 5.64)
Zhang et al, 201337;
Wu et al, 201125
162 91.7 (99/108) 68.5 (37/54) 23.2 4 (2, 13) 1.34 (1.11, 1.62)
Zhao et al, 201338;
Zhao et al, 201228
160 92.5 (98/106) 63.0 (34/54) 29.5 3 (2, 8) 1.47 (1.19, 1.81)
Zhang et al, 201336;
Zhao et al, 201327
101 86.6 (58/67) 55.9 (19/34) 30.7 3 (2, 14) 1.55 (1.13, 2.12)
Xu, 201331 273 76.0 (95/125) 55.8 (72/129) 20.2 5 (3, 14) 1.36 (1.13, 1.63)
Total 1093 75.0 (468/624) 48.2 (217/450) 26.8 4 (3, 7) 1.45 (1.31, 1.60)
Abbreviations: CI: confidence interval; CHM: Chinese herbal medicine; N: numbers of participants; NNT: number needed to treat;
RR: relative risk.
152 Y. Guo et al.treatment with CHM versus the placebo was 1.41 (95% CI,
1.28e1.56), with significant heterogeneity detected among
studies (c2 Z 13.60, P Z .02, I2 Z 63%) (Fig. 4A). The
sensitivity analysis was conducted and indicated using the
Che’s study,31 which might have been the main contributor
towards the heterogeneity. As a result, Che’s study was
excluded and the remaining 5 articles had no significant
heterogeneity (c2Z 5.83, PZ .21, I2Z 31%). Based on the
fixed effects model, the overall effect test (Z Z 6.17,
P < .00001) performed found a significant difference in CMS
improvement between the CHM group and the placebo group
(pooled RR, 1.36; 95% CI, 1.23e1.50) (Fig. 4B).
Quality of life improvement
Among the 10 included studies, 7 trials stated that there
was an improvement in quality of life with CHM therapy andplacebo,29e32,34,37,38 while Che’s study31 provided incom-
plete data that could not be further extracted. Of these 6
studies (698 participants),29,30,32,34,37,38 4 studies
completed in China applied the Medical Outcomes Study
(MOS) 36-item short-form health survey (SF-36) as an eval-
uation tool,32,34,37,38 while the 2 trials completed in Korea
adopted the functional dyspepsia-related quality of life
(FD-QoL) questionnaire.29,30 Additionally, in this meta-
analysis, the sum of the physical component summary
(PCS) score and the mental component summary (MCS)
score was calculated as the result of SF-36. Since statistical
heterogeneity was not detected among these studies
(c2Z 3.84, PZ .57, I2Z 0%), the fixed effects model was
applied. According to the outcome of the hypothesis test
(Z Z 3.80, P Z .0001), CHM resulted in a better improve-
ment in quality of life in comparison with the placebo
(pooled SMD, 0.30; 95% CI, 0.15e0.45) (Fig. 5).
Figure 3 Forest plot of the global symptom improvement of the Chinese herbal medicine (CHM) group versus the placebo group in
functional dyspepsia.
Figure 4 (A) Forest plot of Chinese medicine syndrome in the Chinese herbal medicine (CHM) group versus the placebo group in
functional dyspepsia patients; (B) forest plot of sensitivity analysis by the exclusion of one study.
Figure 5 Forest plot of quality of life improvement in the Chinese herbal medicine (CHM) group versus the placebo group in
functional dyspepsia patients.
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154 Y. Guo et al.Adverse events
All included studies mentioned adverse events, but only 4
studies reported the details.29,30,33,35 Thirty (7.8%) of the
386 participants reported adverse events in the CHM group
compared to 28 (7.3%) of 385 participants assigned to the
placebo group. Under the fixed effects model, there was no
significant difference between the CHM group and the
placebo group in the incidence of adverse events (pooled
RR, 1.06; 95% CI, 0.66e1.70) according to the result of the
overall effect test (Z Z 0.23, P Z .82), with no heteroge-
neity between results (c2Z 2.97, PZ .40, I2Z 0%) (Fig. 6).Discussion
Our meta-analysis appears to show that CHM is effective for
FD, with an NNT value of 4 when data of global dyspepsia
symptoms were pooled from all included studies. Further-
more, the differences in both CMS and quality of life be-
tween the CHM therapy and placebo groups were
statistically significant (P  .05), which indicates that CHM
has a greater impact on the improvement of CMS and
quality of life compared with placebo. Meanwhile, there
was no statistically significant difference between CHM and
placebo groups in the incidence of adverse events, which
illustrates that CHM may be used as an effective and safe
treatment for FD.
The methodological assessment was conducted based
on the Cochrane collaboration’s tool for assessing risk of
bias. We chose the fixed effects model to establish the
hypothesis test in cases where there was an acceptable
level of heterogeneity. However, statistical heterogeneity
was found among the 6 studies that reported CMS
improvement.31,32,34e37 Based on the results of the sensi-
tivity analysis, we speculated that Che’s study31 might be
the main cause of heterogeneity, due to the different
diagnostic criteria of syndrome differentiation. Syndrome
differentiation has a crucial influence on the assessment
of CMS improvement and the standard of diagnosis of CMS
in Che’s study was inconsistent with the determinative
diagnoses used in other studies.32,34e37 The diagnostic
criterion of CMS in Che’s study was reported in accordance
with a draft of a scheme published in 2003,40 while 4 of
the remaining 5 studies used the Guiding Principle for
Clinical Research on New Drugs of Traditional Chinese
Medicine as the diagnostic criteria32,34,36,37,41 and theFigure 6 Forest plot of adverse events in the Chinese herbal m
dyspepsia patients.final study adopted a consensus published in 2010.35,42
Both of these tools have been widely recognized in the
field of TCM and are more highly regarded than the draft
used in Che’s study.
There are several limitations of this research, some of
which relate to the nature of the included studies. Two
articles31,35 did not mention the methods used to generate
randomization, one31 of which did not report the method of
allocation concealment, which may have resulted in se-
lection biases. There were also potential performance
biases due to blinding methods and incomplete information
in 3 studies.31,32,35 Considering the use of ITT analyses and
publication of research programs, potential attrition and
reporting biases cannot be neglected. In addition, it should
be noted that the longest duration of therapy in these 10
studies was 8 weeks, indicating that the long-term efficacy
of CHM in FD needs to be observed in future studies.
Although, conventional treatments are efficacious for FD
to a certain degree,21,43e45 there is still a considerable
proportion of patients who do not experience relief of
persistent symptoms,6 thus there is a pressing need for
more effective therapies in FD. Several meta-analyses
confirmed that CHM appears to be an effective alterna-
tive for FD therapy but with poor-quality evidence, limited
by the particular herbal formulations used.16e18 This un-
derlines the importance of the current meta-analysis,
which focuses on randomized, double-blind, placebo-
controlled clinical trials without the limitation of herbal
formulations and highlights that CHM appear to be more
efficacious than placebos for FD.
The mechanism of action of CHMs in FD may be related
to gastric motility, receptive relaxation, visceral hyper-
sensitivity, and the neuroendocrine system. Three studies
showed that CHM improved gastric motility through gastric
emptying tests based on various techniques, including
radiopaque barium markers,36 radionuclide,35 and ultra-
sound.32 Park’s study also showed Banha-sasim-tang (Pine-
llia Decoction to Drain the Epigastrium in TCM) regulated
gastric motility, as determined by electrogastrography
(EGG).30 Many experimental and clinical studies have
demonstrated that Rikkunshito (Six Gentlemen Decoction;
Liu Jun Zi Tang in pinyin) may be beneficial for dyspepsia
symptoms by altering the gastric accommodation reflex,
increasing gastric motility, improving delayed gastric
emptying, and regulating gastrointestinal hormones, sug-
gesting that Rikkunshito has prokinetic effects on gastro-
intestinal disorders.46e50edicine (CHM) group versus the placebo group in functional
Efficacy of Chinese herbal medicine in functional dyspepsia 155Additionally, there were regional differences in the
evaluation methods of the articles included. CHM is widely
accepted in Asia, especially in China, Japan, and Korea,
and various clinical trials and mechanistic investigations
have been performed in these countries. However, in this
study, we observed that evaluation methods varied among
studies. SF-36 is widely used in China to measure changes
in quality of life,31,32,34,37,38 while the FD-QoL question-
naire is popular in clinical trials conducted in Korea.29,30
Moreover, the methods adopted to estimate improve-
ment of global symptoms and gastric motility varied in
studies, and even the diagnostic criteria of syndrome
differentiation were diverse, which might lead to
increased difficulties in evaluating the work of systematic
reviews. Therefore, there is a need for unified evaluation
of protocols using internationally accepted standards in
clinical trials for FD.
Conclusions
In conclusion, this meta-analysis demonstrates CHM ap-
pears to be more efficacious than placebos in the treatment
of FD, as evidenced by improvements seen in the CHM group
in global dyspepsia symptoms, CMS, quality of life, and the
safety of the drug. However, considering the limited
quantity of the literature included, well-planned, long-
term, and transnational cooperative studies are necessary
to provide credible evidence.
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